Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure.

Literature DB >> 24189264

Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure.

Thomas Goldner¹, Christine Hempel, Helga Ruebsamen-Schaeff, Holger Zimmermann, Peter Lischka.

Abstract

Letermovir is a novel antiviral compound currently in clinical development for the prevention of human cytomegalovirus (HCMV) infections. In contrast to all currently approved anti-HCMV drugs that target the viral DNA polymerase, letermovir acts via a distinct mode of action involving the viral terminase subunit pUL56. To extend our understanding of potential letermovir resistance mechanisms, we used marker transfer to characterize mutations identified in letermovir-resistant HCMV variants that were selected in cell culture.

Entities: Chemical Species

Mesh：

Substances：

Year: 2013 PMID： 24189264 PMCID： PMC3910730 DOI： 10.1128/AAC.01794-13

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

18 in total

1. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase.

Authors: Thomas Goldner; Guy Hewlett; Nicole Ettischer; Helga Ruebsamen-Schaeff; Holger Zimmermann; Peter Lischka
Journal: J Virol Date: 2011-07-13 Impact factor: 5.103

2. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246.

Authors: D R Kaul; S Stoelben; E Cober; T Ojo; E Sandusky; P Lischka; H Zimmermann; H Rubsamen-Schaeff
Journal: Am J Transplant Date: 2011-05 Impact factor: 8.086

3. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses.

Authors: Manfred Marschall; Thomas Stamminger; Andreas Urban; Steffen Wildum; Helga Ruebsamen-Schaeff; Holger Zimmermann; Peter Lischka
Journal: Antimicrob Agents Chemother Date: 2011-11-21 Impact factor: 5.191

4. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action.

Authors: J Reefschlaeger; W Bender; S Hallenberger; O Weber; P Eckenberg; S Goldmann; M Haerter; I Buerger; J Trappe; J A Herrington; D Haebich; H Ruebsamen-Waigmann
Journal: J Antimicrob Chemother Date: 2001-12 Impact factor: 5.790

5. Antiviral treatment of cytomegalovirus infection: an update.

Authors: Georg Härter; Detlef Michel
Journal: Expert Opin Pharmacother Date: 2012-02-02 Impact factor: 3.889

6. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products.

Authors: I Buerger; J Reefschlaeger; W Bender; P Eckenberg; A Popp; O Weber; S Graeper; H D Klenk; H Ruebsamen-Waigmann; S Hallenberger
Journal: J Virol Date: 2001-10 Impact factor: 5.103

7. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product.

Authors: M R Underwood; R J Harvey; S C Stanat; M L Hemphill; T Miller; J C Drach; L B Townsend; K K Biron
Journal: J Virol Date: 1998-01 Impact factor: 5.103

Review 8. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes.

Authors: Meike Chevillotte; Jens von Einem; Benjamin M Meier; Feng-Mao Lin; Hans A Kestler; Thomas Mertens
Journal: Antiviral Res Date: 2009-10-22 Impact factor: 5.970

9. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246.

Authors: Peter Lischka; Guy Hewlett; Tobias Wunberg; Judith Baumeister; Daniela Paulsen; Thomas Goldner; Helga Ruebsamen-Schaeff; Holger Zimmermann
Journal: Antimicrob Agents Chemother Date: 2010-01-04 Impact factor: 5.191

10. The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89.

Authors: Eva Maria Borst; Jennifer Kleine-Albers; Ildar Gabaev; Marina Babic; Karen Wagner; Anne Binz; Inga Degenhardt; Markus Kalesse; Stipan Jonjic; Rudolf Bauerfeind; Martin Messerle
Journal: J Virol Date: 2012-11-21 Impact factor: 5.103

32 in total

1. Caution Is Required before Recommending Wide Use of Letermovir as Salvage Therapy for Cytomegalovirus Diseases.

Authors: Pierre Frange; Marianne Leruez-Ville
Journal: Antimicrob Agents Chemother Date: 2019-04-25 Impact factor: 5.191

2. Advances in the Development of Therapeutics for Cytomegalovirus Infections.

Authors: Edward Acosta; Terry Bowlin; Jennifer Brooks; Lillian Chiang; Islam Hussein; David Kimberlin; Lawrence M Kauvar; Randi Leavitt; Mark Prichard; Richard Whitley
Journal: J Infect Dis Date: 2020-03-05 Impact factor: 5.226

3. Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in UL56 and UL54 Genes.

Authors: Jocelyne Piret; Nathalie Goyette; Guy Boivin
Journal: Antimicrob Agents Chemother Date: 2017-10-24 Impact factor: 5.191

9. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.

Authors: Lauren Cherrier; Aasya Nasar; Kellie J Goodlet; Michael D Nailor; Sofya Tokman; Sunwen Chou
Journal: Am J Transplant Date: 2018-10-29 Impact factor: 8.086

10. Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance.

Authors: Sunwen Chou
Journal: Antimicrob Agents Chemother Date: 2015-08-10 Impact factor: 5.191